They detected the current presence of the CCR3 protein in eye tissue from humans with AMD however, not in that of individuals of similar age who did not have the disease. When they blocked CCR3, either with medications or through genetic engineering, a decrease was seen by them in the generation of abnormal arteries. Drugs targeting CCR3 were more effective than those targeting VEGF considerably, meaning this may represent a fresh therapy for the two-thirds of sufferers that do not react to current treatment. The researchers now may turn to see if levels of the protein could be detected in the bloodstream to be able to identify those who are at risk of developing the disease.This revenue from Merck shall not be recurring over the rest of 2010. In addition, revenue contains $2.8 million from Merck for ARIAD’s services offered in-may and June 2010 under the terms of the restructured agreement. THE BUSINESS reported operating expenditures of $17.june 30 8 million for the quarter ended, 2010, as compared to $20.6 million for the same period in 2009 2009, and operating expenses of $37.2 million for the six-month period ended June 30, 2010, as compared to $42.5 million for the same period in 2009 2009. The reduces in operating expenditures for these periods reflect mainly the assumption by Merck of completely of the costs of ridaforolimus development, commercialization and manufacture starting on the effective time of the restructured agreement.